How to Manage Placebo Response Rate in Atopic Dermatitis (AD) – Placebo-Response Rates in AD
Welcome to the first article in the series on placebo response rate in atopic dermatitis. This series aim to explore strategies on how to ensure a reasonable response rate and dive into the analysis of high response rates in AD. This inaugural article will explore the various factors influencing placebo response rates, including the disease under study, mode […]
Measuring Success: Navigating the Top 3 Clinical Outcome Assessments in Atopic DermatitisâŻâŻ
The selection of patient-reported outcomes (PROs) and clinician-reported outcomes (ClinROs) is crucial for the results of clinical trials investigating atopic dermatitis (AD). The top 3 clinical outcome assessments (COAs) are: 1. Eczema Severity Index (EASI)⯠The EASI quantifies the severity of a subjectâs AD based on both lesion severity and the percentage of body surface […]
Dr. Robert Bissonnette and Dr. Kim Papp on Alopecia Areata Insights
In collaboration with Probity Medical Research (PMR) Dr.âŻRobert Bissonnette from Innovaderm Research and Dr.âŻKim Papp from Probity Medical Research (PMR) met at the 2023 EADV for an engaging conversation focused on the intricacies of early phase studies and explored the significant challenges of conducting vitiligo studies. In this article, we shift the focus on alopecia areata (AA) studies insights, exploring the […]
The Role of Skin barrier Dysfunction in Atopic DermatitisâEarly Childhood
Atopic dermatitis (AD) is a skin condition that has origins in early childhood. This article explores the groundbreaking work of Dr. Alan D. Irvine and his team, who have dedicated years of research to understand the prevalence of AD on the faces of infantâs cheeks provides valuable insights into the early onset of AD, contributing […]
The Role of Skin barrier Dysfunction in Atopic DermatitisâImmune Dysregulation
The relationship between skin barrier dysfunction and immune dysregulation in atopic dermatitis (AD) is well established and has been extensively studied. The immune system has evolved to respond to various pathogens through 3 types of immunity, with AD falling under typeâŻ2, an inflammation disease. Skin Barrier Dysfunction and Immune Dysregulation Interplay When the skin barrier […]
The Role of Skin barrier Dysfunction in Atopic DermatitisâEnvironmental Impact
Atopic Dermatitis (AD) presents a multifaceted pathogenesis involving different interactions between epidermal barrier dysfunction, immune dysregulation, and dysbiosis. This article will expand on how these factors influence each other and explore potential strategies to modulate their effects. This strategic emphasis is grounded in the rationale that targeting immunological systems provides a more accessible and druggable […]
The Role of Skin barrier Dysfunction in Atopic DermatitisâEnvironmental Influences
Consider the shift from an aqueous to an arid environment, like moving from the sterile, xenobiotic womb to enter the world. This transition triggers a rapid breakdown of filaggrin (FLG) in the skin, as it senses the absence of an aqueous environment and metabolizes FLG to produce natural moisturizing factors. FLG is stored as a […]
Innovaderm’s leading expertise and experience in advancing the science of dermatology is to be featured at the american academy of dermatology (AAD) late breaking session
Innovadermâs leading expertise and experience in advancing the science of dermatology is to be featured at the American Academy of Dermatology (AAD) late breaking session on March 18, 2023. Dr. Robert Bissonnette will be presenting the results of a recent phase III trial for a potential new treatment for moderate-to-severe CHE.  The authors of the abstract are […]
Dr. Robert Bissonnette and Dr. Kim Papp on Navigating the Challenges of Vitiligo Research Trials
In collaboration with Probity Medical Research (PMR) Dr. Bissonnette from Indero (Formerly Innovaderm) and Dr. Papp from Probity Medical Research (PMR) took a moment between presentations at the 2023 EADV for an interesting industry talk where the duo covered the intricacies of early phase studies and some of the main challenges encountered with conducting alopecia areata (AA) studies. However, the […]
